Avenna Biomarkers for Chronic Inflammatory Diseases (cIDs)

At Avenna we use molecular and physiological biomarkers to measure the progression of chronic inflammatory diseases (cIDs).Β  GlyHealth-Index (GHI) is one such biomarker which we are co-developing with our sister company Ludger, www.ludger.com).

The following video overviews how we are using our GlyHealth biomarkers to enhance clinical trials of anti-inflammatory biologic drugs as well as medical, and wellness applications.